Syndax Pharmaceuticals (SNDX) Earnings Analysis

Syndax Pharmaceuticals (SNDX) next reports earnings on 2026-08-03, consensus EPS -0.45 USD. Last quarter (2026-04-30) it beat with EPS -0.48 USD vs -0.59 USD est (+18.6%). It has beaten estimates in 5/7 recent quarters (71%). Trailing P/E -7.88.

Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades

When does SNDX next report earnings?

Next earnings date2026-08-03
Consensus EPS estimate-0.45 USD
Revenue estimate0.08B

SNDX earnings history — beats and misses

Quarter (report date)EPS actualEPS est.SurpriseResult
2026-04-30-0.48 USD-0.59 USD+18.6%Beat
2026-02-26-0.78 USD-0.58404 USD-33.6%Miss
2025-11-03-0.7 USD-0.74 USD+5.4%Beat
2025-08-04-0.83 USD-1 USD+17%Beat
2025-05-05-0.98 USD-1.04 USD+5.8%Beat
2025-03-03-1.1 USD-1.08 USD-1.9%Miss
2024-08-01-0.8 USD-0.91 USD+12.1%Beat

Beat rate: 5/7 (71%) over reported quarters with consensus data.

SNDX valuation and analyst view

Trailing P/E-7.88
Trailing EPS-2.8082 USD
Price / book45.89
Dividend yield0.00%
Market cap1.95B
Analyst consensusBuy (20 buy / 2 hold / 0 sell)
Avg price target38.5 USD

Related research pages

Frequently asked questions

When is Syndax Pharmaceuticals (SNDX)'s next earnings date?

Syndax Pharmaceuticals is next scheduled to report on 2026-08-03, with a consensus EPS estimate of -0.45 USD and revenue estimate of 0.08B.

Did SNDX beat earnings last quarter?

In its 2026-04-30 report, SNDX posted EPS of -0.48 USD versus a -0.59 USD estimate — a beat of 18.6%.

What is SNDX's earnings track record?

Over the last 7 reported quarters with consensus data, SNDX beat estimates 5 times (71%).

What is SNDX's current P/E ratio and EPS?

SNDX trades at a trailing P/E of -7.88 on trailing EPS of -2.8081988383348553 USD.

What do analysts rate SNDX?

Analyst consensus is "Buy" across 22 ratings (0 strong buy, 20 buy, 2 hold, 0 sell, 0 strong sell). Average 12-month price target: 38.5 USD.